Engineered immune cells take on rare autoimmune disease in kids

NCT ID NCT06792344

Recruiting now Disease control Sponsor: The Children's Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether a type of immunotherapy called CAR-T cells can safely treat children with severe systemic sclerosis, a rare autoimmune disease that causes skin thickening and organ damage. The treatment involves collecting the child's own immune cells, engineering them to target a protein called CD19, and infusing them back. The study will monitor skin improvement and side effects in 12 participants over 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-CD19 CAR-T cells
What this could lead to: If successful, this could offer a new treatment option for children with severe systemic sclerosis that hasn't responded to standard therapies.
What could go wrong: This is a very early phase 1 trial with only 12 participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

Children's Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 0571, China
Children's Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310053, Christmas Island

More trials for these conditions

Other studies related to the condition(s) this trial covers.